A new analysis confirmed the importance of known prognostic factors such as performance status and tumor grading for having a long-term outcome in patients treated with pazopanib for metastatic soft tissue sarcoma. In addition, hemoglobin at baseline was found to be a new prognostic factor.
A trial comparing pazopanib and sunitinib found pazopanib to have better safety and health-related quality-of-life profiles among persons with metastatic renal cell carcinoma.
Maintenance therapy with pazopanib is linked to longer progression-free survival after surgery for advanced disease.
The American Society of Clinical Oncology has released a nearly 100-page report detailing the year’s most significant developments in cancer.
Kidney cancer drugs in development could improve patients’ quality of life and allow more effective treatment, according to Professor Robert Hawkins of Manchester University.
